The Neos Therapeutics team is dedicated to creating high-quality products and partnering with pharmaceutical and consumer healthcare companies to address key medical needs. Neos Therapeutics’ research and development (R&D) and fully integrated state of the art, FDA approved manufacturing facility is located in the Dallas/Fort Worth area.
Nora Therapeutics is a specialty biopharmaceutical company focused on developing therapeutics to address clinical unmet needs in reproductive medicine. Nora’s lead compound, NT100, is a novel treatment being studied to improve pregnancy success rates and outcomes for women who have undergone multiple unsuccessful in vitro fertilization (IVF) procedures. NT100 is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract. NT100’s mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance.
The Neos Therapeutics team is dedicated to creating high-quality products and partnering with pharmaceutical and consumer healthcare companies to address key medical needs. Neos Therapeutics’ research and development (R&D) and fully integrated state of the art, FDA approved manufacturing facility is located in the Dallas/Fort Worth area.
BetterDoctor helps validate and deliver accurate provider data to health plans, health systems, and hundreds of other companies via its API — from startups to publicly traded ones. This ultimately helps achieve the mission of helping consumers find the healthcare they need. Today, BetterDoctor's data platform and APIs power 9 health plans, 350 companies, 1,500 developers, helping millions of people find the right doctor each month. Health Plans BetterDoctor uses multi-modal outreach to drive providers to attest their information on BetterDoctor's online portal. API Partners BetterDoctor brings transparency to doctor data. Their real-time platform, master database and API services enable everyone to add doctor data to their systems, websites and applications. Today, BetterDoctor API and data tools power health insurance companies, healthcare startups and doctor search tools. https://betterdoctor.com/developers
Newbridge Pharmaceuticals, a pharmaceutical, biologics, and medical device company, engages in the sale and marketing of healthcare products. It offers oncology and supportive care products, such as CLASTEON, a bisphosphonate, which treats problems associated with bone metastasis; SANCUSO, a granisetron transdermal system for the prevention of chemotherapy induced nausea and vomiting; and GLICONORM, a film-coated divisible tablet for the treatment of non-insulin dependent diabetes mellitus. The company provides therapeutic products for diseases, such as diabetes, obesity, oncology, and cardiovascular diseases, as well as for other metabolic disorders. It serves biotechnology and pharmaceutical companies in the Middle East, Africa, Turkey, and Caspian Regions. Newbridge Pharmaceuticals was founded in 2007 and is based in Dubai, the United Arab Emirates.
Catalyst Biosciences is a research and clinical development biopharmaceutical company. They focus on addressing unmet medical needs in rare disorders of the complement and coagulation systems. They create novel catalytic biopharmaceutical products based on engineered human proteases.
Odyssey Thera, Inc., a biopharmaceutical company, develops cellular pharmacology strategy for the identification of medicines for human diseases. It focuses on the identification and development of treatment therapies for cancer. The company was formerly known as Odyssey Pharmaceuticals. Odyssey Thera, Inc. is based in San Ramon, California.
Strand Life Sciences provides bioinformatics solutions with advanced visualization, predictive systems modeling, data integration, and scientific context management components to transform raw data into actionable insights. The company employs 200 people, mostly in Bangalore, India, and services both the research and clinical markets. Strand enjoys three advantages over the competition globally: superior software analytics, superior curation of gene variants, and a major cost advantage for DNA test interpretation. When combined, Strand is finding a rapidly growing demand for its StrandOmics software platform, which hospitals and service providers can use to service their patients and healthcare clients. With every sequence and gene test, the company’s cloud database gets more valuable with related metadata, which can be used to improve future analytics, thereby creating an additional demand for StrandOmics. Strand has developed the most advanced software for analyzing DNA sequences. Today, 1,400 research institutions worldwide use Strand’s software under the product names GeneSpring (marketed by Agilent) and Avadis (marketed by Strand). The company reached profitability in 2007, and in early 2013, the company began to service the clinical market in India. It opened its own DNA sequence and gene panel wet lab in Bangalore, India, and in December, the company opened a lab which it operates in the 1,400-bed Mazumdar-Shaw Cancer Center in Bangalore. By the end of 2013, Strand was servicing the gene testing and DNA sequence analysis needs of over 100 hospitals in India, and in 2014 it has begun to expand into the US market.
MabVax is a clinical stage biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies resulting from two integrated and successful technology platforms. The first is a series of vaccines developed at Memorial Sloan-Kettering Cancer Center (MSKCC) and licensed to MabVax. Two of the company’s lead cancer vaccines are currently undergoing proof of concept Phase II multi-center clinical trials for the treatment of soft tissue sarcoma and ovarian cancer. Both trials have received $2MM or more in federal grant monies. The second is a human antibody discovery platform developed internally and based on the protective immune responses generated from patients who have been successfully immunized against targeted cancers with the licensed vaccines. The company’s lead human antibody candidate is undergoing preclinical evaluation for development against colon, pancreatic and breast cancers and has received $1.1MM in federal grant monies.
Cobalt Technologies develops technologies that focuses and designed for biofuels. Cobalt is pioneering science that makes possible a new generation of fuels that burn cleaner, are more cost-effective and have a smaller environmental impact. It was founded in 2005 and headquartered in Mountain View, California.
Catalyst Biosciences is a research and clinical development biopharmaceutical company. They focus on addressing unmet medical needs in rare disorders of the complement and coagulation systems. They create novel catalytic biopharmaceutical products based on engineered human proteases.
Waterstone Pharmaceuticals is a private US based company with research, development & manufacturing capabilities in Wuhan, China. Waterstone Pharmaceuticals engages in activities ranging from drug discovery of proprietary new chemical entities, custom development & manufacturing services, and generic drug development and manufacturing.
AliveCor, Inc. is a technology company that develops digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile devices. Its flagship product, KardiaMobile, provides instant detection of common heart arrhythmias and allows users to track blood pressure and weight, as well as store recorded EKGs. The company also offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed readings with their healthcare providers. Additionally, AliveCor has introduced KardiaCare, a digital health subscription service that facilitates the management of heart health at home. Founded in 2010 and headquartered in Mountain View, California, AliveCor is recognized for its pioneering efforts in using machine learning techniques to enhance cardiac care and improve early detection of conditions such as atrial fibrillation.
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.
WhiteGlove Health has become a leader in the healthcare industry through providing an extraordinary healthcare experience for members and providing significant cost savings for health plans through reduced insurance claims and reductions in unnecessary utilization. Their comprehensive healthcare strategy is to provide the highest quality care at a predictable cost through highly-skilled nurse practitioners supported by registered nurses in collaboration with physicians, hospitals, other health care providers and carriers. Since 2007, WhiteGlove Health’s highly trained and experienced clinical team comprised of board-certified Nurse Practitioners and Registered Nurses have been making house calls, office calls and providing telephonic support to help members feel better, faster. Their initial focus as a mobile healthcare provider for acute needs and managing chronic conditions has paved the way for the successful introduction of their Value-Based Care division in 2014 which leverages their clinical expertise and ability to deliver provider care to high risk/high cost patients for their Medicare and Medicaid health plan customers. Value-Based Care is conducted at-home or at a Skilled Nursing Facility (SNF) and allows health plans the ability to care for their most challenging patients. Their Solution offers care designed to reduce hospital admissions, re-admissions and prevent unnecessary visits to an emergency room. A WhiteGlove Health Nurse Practitioner has the ability to order or discontinue medications, add home health or durable medical Equipment (as needed) and routinely communicate with the Primary Care Physician on behalf of the patient. The WhiteGlove Health strategy of prompt follow-up and proactive intervention allows us to carefully monitor patients and manage utilization. In June 2014, WhiteGlove Health acquired Glenridge Healthcare Solutions, a leading consulting, technology and professional services firm, founded in 1997 and headquartered in Maryland. Together, their companies are creating more opportunities and efficiencies than they could have achieved independently. Glenridge continues to partner with customers nationwide by providing a seasoned team, advanced data analytic capabilities and state-of-the art technology to their established impressive portfolio.
WaveTec Vision is a small company with a big idea — and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.
Cobalt Technologies develops technologies that focuses and designed for biofuels. Cobalt is pioneering science that makes possible a new generation of fuels that burn cleaner, are more cost-effective and have a smaller environmental impact. It was founded in 2005 and headquartered in Mountain View, California.
Virdia, formerly HCL CleanTech, a leading developer of cellulosic sugars. Virdia is a leading developer of cellulosic sugars and lignin for use in the renewable chemicals, bio-energy and nutrition industries. The company's CASEâ„¢ proprietary process converts a wide range of cellulosic feedstock, including wood, energy crops and agricultural residues into highly refined sugars and lignin. This low-temperature process delivers the highest yields of sugars from biomass, and has a very light environmental footprint due to the near complete recycling of acids and solvents used in manufacturing. The company is led by a seasoned management team with decades of experience in corn processing, chemicals and biochemicals industries.
ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. ADMA also operates ADMA BioCenters, FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacturing of the Company’s lead product candidate RI-002.
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.
AliveCor, Inc. is a technology company that develops digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile devices. Its flagship product, KardiaMobile, provides instant detection of common heart arrhythmias and allows users to track blood pressure and weight, as well as store recorded EKGs. The company also offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed readings with their healthcare providers. Additionally, AliveCor has introduced KardiaCare, a digital health subscription service that facilitates the management of heart health at home. Founded in 2010 and headquartered in Mountain View, California, AliveCor is recognized for its pioneering efforts in using machine learning techniques to enhance cardiac care and improve early detection of conditions such as atrial fibrillation.
Newbridge Pharmaceuticals, a pharmaceutical, biologics, and medical device company, engages in the sale and marketing of healthcare products. It offers oncology and supportive care products, such as CLASTEON, a bisphosphonate, which treats problems associated with bone metastasis; SANCUSO, a granisetron transdermal system for the prevention of chemotherapy induced nausea and vomiting; and GLICONORM, a film-coated divisible tablet for the treatment of non-insulin dependent diabetes mellitus. The company provides therapeutic products for diseases, such as diabetes, obesity, oncology, and cardiovascular diseases, as well as for other metabolic disorders. It serves biotechnology and pharmaceutical companies in the Middle East, Africa, Turkey, and Caspian Regions. Newbridge Pharmaceuticals was founded in 2007 and is based in Dubai, the United Arab Emirates.
FerroKin Biosciences
Series B in 2010
Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.
Gevo brings renewable and cost-effective fossil fuel alternatives to consumers worldwide will be absolutely essential to meet increasing energy demands and save their earth from global warming. Gevo focuses on the production of isobutanol.
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.
FerroKin Biosciences
Venture Round in 2009
Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.
PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; and FungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts.
Gevo brings renewable and cost-effective fossil fuel alternatives to consumers worldwide will be absolutely essential to meet increasing energy demands and save their earth from global warming. Gevo focuses on the production of isobutanol.
CareDx is a molecular diagnostics company. They offer noninvasive surveillance tests to help identify injuries and rule out rejection. They deliver solutions that support a broad spectrum of needs, from initial matching to post-transplant monitoring and care.
Virdia, formerly HCL CleanTech, a leading developer of cellulosic sugars. Virdia is a leading developer of cellulosic sugars and lignin for use in the renewable chemicals, bio-energy and nutrition industries. The company's CASEâ„¢ proprietary process converts a wide range of cellulosic feedstock, including wood, energy crops and agricultural residues into highly refined sugars and lignin. This low-temperature process delivers the highest yields of sugars from biomass, and has a very light environmental footprint due to the near complete recycling of acids and solvents used in manufacturing. The company is led by a seasoned management team with decades of experience in corn processing, chemicals and biochemicals industries.
Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.
Ikano Therapeutics a specialty pharmaceutical company, focuses on developing nasal spray drug products.
Catalyst Biosciences is a research and clinical development biopharmaceutical company. They focus on addressing unmet medical needs in rare disorders of the complement and coagulation systems. They create novel catalytic biopharmaceutical products based on engineered human proteases.
Osprey Pharmaceuticals USA is a clinical stage company focused on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases. The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases. The Company’s lead candidate, CCL2-LPM targeting the CCR2 chemokine receptor expressed by certain pathologically activated leukocytes is in a Phase Ib clinical trial for the treatment of IgA nephropathy.
BioImagene, Inc. provides digital pathology solutions for clinical diagnostics and drug discovery applications. It develops and distributes integrated hardware and software systems to acquire, view, share, manage, archive, and analyze tissue images in pathology laboratories. The company offers IHC algorithms, such as HER2, ER/PR, and p53 for breast cancer; Ki67 for breast, brain, and prostate cancers; CD138 for multiple myeloma; CD3/CD20 for lymphoma; iSlide input device, a device that allows pathologists to use a microscope interface to manipulate digital images of slides; and iScan Coreo Au digital slide scanners that enable digital pathology applications, such as image analysis, telepathology, remote microscopy, and education. It serves cancer research laboratories, academic medical centers, community hospitals, reference laboratories, teaching hospitals, biotech companies, and pharmaceutical companies. BioImagene, Inc. was founded in 2003 and is based in Sunnyvale, California.
Wellpartner is a nationally recognized provider of pharmacy distribution solutions for health plans, Medicaid programs, and safety net organizations throughout the country. Dedicated to lowering the cost of medications, we offer innovative approaches that improve pharmacy care for individuals through the use of retail contract pharmacy services. We are the largest independent provider of contract pharmacy program services in the nation.
Gevo brings renewable and cost-effective fossil fuel alternatives to consumers worldwide will be absolutely essential to meet increasing energy demands and save their earth from global warming. Gevo focuses on the production of isobutanol.
NanoVasc is a pioneering medical device company specializing in the design and manufacture of biomimetic materials. These materials are engineered to be non-thrombogenic, durable, and capable of maintaining long-term patency. Utilizing an electrospinning process, NanoVasc produces scaffolds in various shapes and sizes, which are then customized with application-specific modifications on the scaffold's surface. These modifications are meticulously crafted to optimize device performance based on its intended deployment location. The company's flagship product is a synthetic vascular graft specifically developed for hemodialysis access. This innovative graft aims to improve patient outcomes by providing a reliable and effective alternative to traditional vascular access methods. NanoVasc's dedication to biomimetic design and precision engineering underscores its commitment to advancing medical solutions that enhance the quality of patient care in vascular health.
PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; and FungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts.
Chlorogen a biopharmaceutical company, engages in the development and manufacture of proteins for human therapy. The company, through its chloroplast transformation technology (CTT), offers plant made drugs for the treatment and prevention of human diseases, as well as for treatment of women's reproductive cancers. Its products include therapeutic proteins in tobacco that are made using chloroplast transformation technology. The chloroplast transformation technology facilitates hyper-expression of recombinant proteins in tobacco chloroplasts. The company offers its chloroplast-tobacco platform for commercial use in food and agriculture. Chlorogen, Inc. was founded in 2002 and is based in St. Louis, Missouri.
Light Sciences Oncology develops cancer and tumor treatment drugs. Additionally, it offers oncology drugs research and development services to treat hepatocellular carcinoma, metastatic colorectal cancer, and glioma. Light Sciences Oncology was founded in 1994 and is headquartered in Bellevue, Washington.
Logical Therapeutics, Inc., a biopharmaceutical company, engages in the development of drugs to treat diseases caused by or associated with excessive inflammation. Its products include LT-NS001, a non-steroidal anti-inflammatory drug for the treatment of chronic inflammatory conditions, such as osteoarthritis; Leptin, a hormone for the regulation of normal body mass and metabolism; and TNF, a hormone that promotes the proliferation of hepatocytes. The company was founded in 2005 and is based in Waltham, Massachusetts.
Phytomedics is committed to quality, technological innovation and research. Their powerful portfolio of overlapping proprietary technologies is targeted to turning green plants into reliable vehicles for discovering and manufacturing proprietary botanical pharmaceuticals and nutraceuticals. NewLeadTM and RhizexTM elicitation and optimization processes greatly enhance the efficacy and reproducibility of plant-derived products and increase the synergy between various chemical components of plant extracts. The Company has developed an efficient and proprietary discovery and lead prioritization process based on high-power bio-informatics, high-tech data mining, efficient activity screening, and an extensive network of international collaborations.
Dreamerz Foods, Inc. provides various natural sleep products. It offers natural sleep beverage, a dietary supplement in the form of an all-natural, creamy, and dairy-based functional sleep beverage. The company also provides chocolate pillows, soothing dairy products, and herbal fruit-flavored mix. It offers its products through stores and online shops. Dreamerz Foods, Inc. was founded in 2006 and is based in San Francisco, California.
Arete Therapeutics is a pharmaceutical company that develops small molecule therapeutics for diabetes and cardiovascular disease.
As of February 23, 2010, The Natural Dentist, Inc. was acquired by Revive Personal Products Company. The company manufactures oral care products in the United States. It offers mouth rinses and toothpastes through stores and online retailers, as well as through phone. The company was formerly known as Woodstock Natural Products Inc and changed its name to The Natural Dentist, Inc. in 2005. The Natural Dentist, Inc. was founded in 1995 and is based in Medford, Massachusetts.
Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.
Attune Foods, Inc. offers probiotic wellness bars. It offers wellness bars in various flavors, including dark chocolate, chocolate crisp, mint chocolate, and blueberry vanilla, as well as chewy chocolate, peanut butter and chocolate, mango peach, wild berry, strawberry bliss, and lemon crème. Attune Foods, Inc. was founded in 2006 and is headquartered in San Francisco, California.
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.
ProteoGenix engages in the development and commercialization of diagnostic testing products for the maternal-fetal health community. Its products include non-invasive diagnostics tests to detect intraamniotic infection, neonatal sepsis, preterm birth, preeclampsia, and down syndrome. ProteoGenix, Inc. was founded in 2002 and is based in Costa Mesa, California with additional offices in Beaverton, Oregon; and Orange County, California.
diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. The company's lead product, the PLAC Test, measures Lp-PLA2 (lipoprotein-associated phospholipase A2) a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. It is plaque rupture and thrombosis, not stenosis, that cause the majority of cardiovascular events. The PLAC Test is the only blood test cleared by the FDA as an aid in assessing risk for coronary heart disease, and ischemic stroke associated with atherosclerosis.
Dreamerz Foods, Inc. provides various natural sleep products. It offers natural sleep beverage, a dietary supplement in the form of an all-natural, creamy, and dairy-based functional sleep beverage. The company also provides chocolate pillows, soothing dairy products, and herbal fruit-flavored mix. It offers its products through stores and online shops. Dreamerz Foods, Inc. was founded in 2006 and is based in San Francisco, California.
As of February 23, 2010, The Natural Dentist, Inc. was acquired by Revive Personal Products Company. The company manufactures oral care products in the United States. It offers mouth rinses and toothpastes through stores and online retailers, as well as through phone. The company was formerly known as Woodstock Natural Products Inc and changed its name to The Natural Dentist, Inc. in 2005. The Natural Dentist, Inc. was founded in 1995 and is based in Medford, Massachusetts.
Neurotech is a privately held biotechnology company developing sight-saving therapeutics for chronic retinal diseases–including indications with significant unmet medical need that, as a whole, represent the largest market opportunity in ophthalmology.
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.
Morphotek is one of the leading companies in the life science industry that develops novel classes of biological-based products to treat cancer, inflammation and infectious diseases. Since its founding in 2000, Morphotek has made extraordinary progress in discovering and developing monoclonal antibodies (mABs) to treat these diseases and continues to develop additional antibody products using its proprietary technologies. Post-graduate research executed by Morphotek’s President and CEO, Dr. Nicholas Nicolaides, during his studies at Johns Hopkins Medical School was the basis for the company’s inception. It was there that Dr. Nicolaides co-invented the company's legacy technology called morphogenics. Along with the honed applications for applying morphogenics for product development refined by the company’s other co-founders, Dr. Philip Sass and Dr. Luigi Grasso, morphogenics has taken Morphotek an incredible distance in the advancement of novel pharmaceutical products and targets.
Cardiokine, Inc., a specialty pharmaceutical company, engages in the development of pharmaceuticals for the prevention and treatment of cardiovascular diseases. Its products include lixivaptan, an orally active vasopressin receptor antagonist for patients with congestive heart failure who suffer from hyponatremia. The company was founded in 2004 and is headquartered in Philadelphia, Pennsylvania.
Sciona provides gene-based personalized health and nutrition analysis and recommendations based on individual diet, lifestyle, and genetic profile. The company's Mycellf Program, which includes a diet and lifestyle questionnaire, makes recommendations for how individuals can make choices that benefit their long-term health. It also offers genetic testing products, which address personal wellness, fitness, and nutritional issues. The company was founded in 2000 and is headquartered in Aurora, Colorado.
Chromatin is a biotech company developing and marketing innovative technologies and products that benefit the agricultural, energy, chemical, nutritional, and pharmaceutical sectors. Chromatin is unlocking the potential of plants to produce greater value and meaningful products for consumers, growers, seed producers, and bioprocessors. Chromatin is commercializing solutions that proactively address key societal challenges such as improving agricultural productivity and increasing renewable energy resources.
Catalyst Biosciences is a research and clinical development biopharmaceutical company. They focus on addressing unmet medical needs in rare disorders of the complement and coagulation systems. They create novel catalytic biopharmaceutical products based on engineered human proteases.
Adlyfe is a biotechnology company founded in the spring of 2003 to bring to market innovative diagnostic products for neurodegenerative diseases. These diseases are correlated to changes in protein conformation, as normally soluble proteins fold into conformations that aggregate and deposit in brain tissue, a process known as amyloidogenesis. Over time, the accumulation of these misfolded and aggregating proteins results in loss of neural cells and brain tissue, and associated symptoms including dementia, motor dysfunction, and other fatal symptoms.
Ikano Therapeutics a specialty pharmaceutical company, focuses on developing nasal spray drug products.
CareDx is a molecular diagnostics company. They offer noninvasive surveillance tests to help identify injuries and rule out rejection. They deliver solutions that support a broad spectrum of needs, from initial matching to post-transplant monitoring and care.
Alinea Pharmaceuticals, Inc., a biopharmaceutical company previously focused on developing new therapeutics for the treatment of diabetes and other metabolic disorders.
Chlorogen a biopharmaceutical company, engages in the development and manufacture of proteins for human therapy. The company, through its chloroplast transformation technology (CTT), offers plant made drugs for the treatment and prevention of human diseases, as well as for treatment of women's reproductive cancers. Its products include therapeutic proteins in tobacco that are made using chloroplast transformation technology. The chloroplast transformation technology facilitates hyper-expression of recombinant proteins in tobacco chloroplasts. The company offers its chloroplast-tobacco platform for commercial use in food and agriculture. Chlorogen, Inc. was founded in 2002 and is based in St. Louis, Missouri.
BioMimetic Therapeutics is a biotechnology company that develops products to help stimulate the body natural tissue regenerative process. The company's products and product candidates include Augment Injectable and Augment Rotator Cuff for several orthopedic and sports medicine indications comprising the treatment of foot and ankle fusions, the stimulation of wrist fracture healing, and the surgical treatment of rotator cuff tears, as well as Augment Tendinopathy Injection for injuries cause of tendon overuse. BioMimetic Therapeutics was founded on 1999 and is headquartered in Franklin, Tennessee.
Brand New Brands
Series A in 2005
Brand New Brands is a groundbreaking new company that brings together the entrepreneurial spirit of a start-up and the resources of an established corporation to create new foods and beverages that promote health and wellness. Brand New Brands uses a portfolio-based incubator model to develop and market the highest potential new functional food business opportunities for the U.S. marketplace. Core to their approach is the commitment to create food and beverage products that are efficacious (by medical standards), honest and transparent in their claims, and satisfying to eat or drink. By vetting and assessing the potential of scores of new product concepts, they take the most promising opportunities and fuse them with talented, passionate and proven entrepreneurial teams who turn ideas into thriving new ventures. They focus their efforts and resources by innovating “category-creating” brand platforms that are capable of crossing over from niche markets to the mainstream in three to five years. They only pursue opportunities where they can claim distinct competitive advantages over large food companies through IP, brand creation or non-traditional distribution. Their strategy is to take the most promising new nutritional technologies and deliver them to the marketplace through great-tasting products with engaging “lifestyle” brands that educate and attract loyal customers and progressive retail partners. They take opportunities to market that are likely to scale quickly due to the convergence of scientific advances, consumer readiness and media attention.
Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. It was founded in 2001 and headquartered in Mountain View, California.
CareDx is a molecular diagnostics company. They offer noninvasive surveillance tests to help identify injuries and rule out rejection. They deliver solutions that support a broad spectrum of needs, from initial matching to post-transplant monitoring and care.
Neosil, Inc. is a dermatology-focused pharmaceutical company with a developed topical hair growth product and that is developing a broad-spectrum topical anti-microbial agent for acne and anti-infective use.
BioMimetic Therapeutics is a biotechnology company that develops products to help stimulate the body natural tissue regenerative process. The company's products and product candidates include Augment Injectable and Augment Rotator Cuff for several orthopedic and sports medicine indications comprising the treatment of foot and ankle fusions, the stimulation of wrist fracture healing, and the surgical treatment of rotator cuff tears, as well as Augment Tendinopathy Injection for injuries cause of tendon overuse. BioMimetic Therapeutics was founded on 1999 and is headquartered in Franklin, Tennessee.
Sciona provides gene-based personalized health and nutrition analysis and recommendations based on individual diet, lifestyle, and genetic profile. The company's Mycellf Program, which includes a diet and lifestyle questionnaire, makes recommendations for how individuals can make choices that benefit their long-term health. It also offers genetic testing products, which address personal wellness, fitness, and nutritional issues. The company was founded in 2000 and is headquartered in Aurora, Colorado.
Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.
Nucleonics
Series B in 2004
Nucleonics is a biotechnology company focused on RNA interference-based therapeutics.
Efficas, Inc., a health-science and technology company, engages in the research, development, and commercialization of products for the nutritional management of the immune system for humans and pets. The company provides EFFICAS CARE, a berry flavored non-prescription medical food for the dietary management of asthma and associated allergies. Efficas, Inc. was founded in 2003 and is headquartered in Boulder, Colorado.
Cardiokine, Inc., a specialty pharmaceutical company, engages in the development of pharmaceuticals for the prevention and treatment of cardiovascular diseases. Its products include lixivaptan, an orally active vasopressin receptor antagonist for patients with congestive heart failure who suffer from hyponatremia. The company was founded in 2004 and is headquartered in Philadelphia, Pennsylvania.
Spectral Genomics, a pioneer in technology for the genome with headquarters in Houston, TX, is a global supplier of innovative products for human genetics and performs Genomic Profiling(SM) services for customers in academic and industrial research laboratories.
Morphotek is one of the leading companies in the life science industry that develops novel classes of biological-based products to treat cancer, inflammation and infectious diseases. Since its founding in 2000, Morphotek has made extraordinary progress in discovering and developing monoclonal antibodies (mABs) to treat these diseases and continues to develop additional antibody products using its proprietary technologies. Post-graduate research executed by Morphotek’s President and CEO, Dr. Nicholas Nicolaides, during his studies at Johns Hopkins Medical School was the basis for the company’s inception. It was there that Dr. Nicolaides co-invented the company's legacy technology called morphogenics. Along with the honed applications for applying morphogenics for product development refined by the company’s other co-founders, Dr. Philip Sass and Dr. Luigi Grasso, morphogenics has taken Morphotek an incredible distance in the advancement of novel pharmaceutical products and targets.
Phytomedics is committed to quality, technological innovation and research. Their powerful portfolio of overlapping proprietary technologies is targeted to turning green plants into reliable vehicles for discovering and manufacturing proprietary botanical pharmaceuticals and nutraceuticals. NewLeadTM and RhizexTM elicitation and optimization processes greatly enhance the efficacy and reproducibility of plant-derived products and increase the synergy between various chemical components of plant extracts. The Company has developed an efficient and proprietary discovery and lead prioritization process based on high-power bio-informatics, high-tech data mining, efficient activity screening, and an extensive network of international collaborations.
They are developing and commercializing proprietary cell-based research and diagnostic products with an initial focus on cancer. They believe that their current and future products can provide significant clinical benefits by giving physicians better information to understand, diagnose, treat and monitor cancer. They design their products to provide physicians and scientists with clinically meaningful information earlier than current diagnostic methods. Their technologies, which they brand as CellTracks, can identify, count and characterize the presence and quantity of a small number of tumor cells present in a blood sample. Their collaborator, Veridex, LLC, or Veridex, a Johnson & Johnson company, submitted a pre-market notification, or 510(k), to the US Food and Drug Administration, or FDA, in May 2003 for use of the CellSearch Epithelial Cell Kit in the management of metastatic breast cancer. They expect that the CellSearch Epithelial Cell Kit will be the initial product launched by Veridex based on their technologies. They believe that their products and underlying technology platforms have other applications in cancer diagnostics, in the development of cancer drugs and in cancer research. In addition, they believe that their proprietary technologies may have applications in other fields of medicine, such as cardiovascular and infectious diseases.
BioMimetic Therapeutics is a biotechnology company that develops products to help stimulate the body natural tissue regenerative process. The company's products and product candidates include Augment Injectable and Augment Rotator Cuff for several orthopedic and sports medicine indications comprising the treatment of foot and ankle fusions, the stimulation of wrist fracture healing, and the surgical treatment of rotator cuff tears, as well as Augment Tendinopathy Injection for injuries cause of tendon overuse. BioMimetic Therapeutics was founded on 1999 and is headquartered in Franklin, Tennessee.
Emerald BioAgriculture Corporation is a privately held company that develops biochemical products to increase crop production. It is dedicated to the development of naturally occurring biochemicals for the enhancement of yields, quality, and disease control in crops grown around the world.
Catalyst Biosciences is a research and clinical development biopharmaceutical company. They focus on addressing unmet medical needs in rare disorders of the complement and coagulation systems. They create novel catalytic biopharmaceutical products based on engineered human proteases.
Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. It was founded in 2001 and headquartered in Mountain View, California.
GeneFormatics is a biotechnology company specializing in structural proteomics.
Morphotek is one of the leading companies in the life science industry that develops novel classes of biological-based products to treat cancer, inflammation and infectious diseases. Since its founding in 2000, Morphotek has made extraordinary progress in discovering and developing monoclonal antibodies (mABs) to treat these diseases and continues to develop additional antibody products using its proprietary technologies. Post-graduate research executed by Morphotek’s President and CEO, Dr. Nicholas Nicolaides, during his studies at Johns Hopkins Medical School was the basis for the company’s inception. It was there that Dr. Nicolaides co-invented the company's legacy technology called morphogenics. Along with the honed applications for applying morphogenics for product development refined by the company’s other co-founders, Dr. Philip Sass and Dr. Luigi Grasso, morphogenics has taken Morphotek an incredible distance in the advancement of novel pharmaceutical products and targets.
Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.
BioMimetic Therapeutics is a biotechnology company that develops products to help stimulate the body natural tissue regenerative process. The company's products and product candidates include Augment Injectable and Augment Rotator Cuff for several orthopedic and sports medicine indications comprising the treatment of foot and ankle fusions, the stimulation of wrist fracture healing, and the surgical treatment of rotator cuff tears, as well as Augment Tendinopathy Injection for injuries cause of tendon overuse. BioMimetic Therapeutics was founded on 1999 and is headquartered in Franklin, Tennessee.
Bruker Cellular Analysis is a cell biology company enabling the exploration of the phenome and mastery of single cells for all labs.
Private Equity Round in 2000
Circe Biomedical, Inc. develops, produces, and commercializes bioartificial organ systems. It develops bioartificial organs from isolated mammalian cells and membranes for patients suffering from acute, end-stage liver failure. The company also develops PancreAssist System, an implantable, bioartificial pancreas for severe insulin-dependent diabetics. Circe Biomedical, Inc. was incorporated in 1999 and is based in Lexington, Massachusetts.
DoubleTwist
Series D in 2000
In December 1999, Pangea Systems became DoubleTwist, Inc. - a new application service provider (ASP)/ Internet company devoted to empowering life scientists. The change reflects a new focus on this Internet portal. DoubleTwist.com integrates powerful tools and data behind automated research agents that retrieve and interpret data based on the user's scientific questions. The company's traditional data warehousing and mining software power the site, enabling life science research through an easy-to-use interface on the Web. DoubleTwist has established a talented and experienced development team of scientific and technical personnel dedicated to building software solutions that address the biological data management needs of life scientists. DoubleTwist's scientific team is comprised of leading experts in their respective fields of biochemistry, molecular biology, protein chemistry, bioinformatics, computer science and computational biology. They come to DoubleTwist from world-renowned institutions, including Stanford University, UCLA, UC Berkeley, UCSF, University of Pennsylvania, Sandoz Pharmaceutical, Onyx Pharmaceutical, Incyte, Molecular Simulations, Molecular Dynamics, Roche and Glaxo Wellcome. The company's software engineers have extensive experience in commercial-grade software systems, with particular expertise in relational database and object-oriented development. They come to DoubleTwist from some of the industry's most successful companies, including Apple, Oracle and IBM.